A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit <a rel="external noopener" href="https://ijgc.bmj.com/content/ijgc/30/Suppl_3/A43.2.full.pdf">the original URL</a>. The file type is <code>application/pdf</code>.
<i title="BMJ Publishing Group Ltd">
Uterine serous carcinoma (USC) carries a poor prognosis and the majority of patients develop recurrence. The study objective was to compare efficacy of chemotherapy regimens in recurrent USC. Methods A retrospective review of patients with USC treated at our institution from 1993 to 2012 was performed. Recurrence-free survival (RFS) was estimated using methods of Kaplan and Meier and modeled via Cox proportional hazards regression. RFS1 was calculated from date of first recurrence to second<span class="external-identifiers"> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1136/ijgc-2020-igcs.76">doi:10.1136/ijgc-2020-igcs.76</a> <a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/xvrimf2i2feg5o2cd3y46yxquq">fatcat:xvrimf2i2feg5o2cd3y46yxquq</a> </span>
more »... rrence. Platinum-sensitivity was defined as recurrence >6 months after platinum-based therapy. Those never exposed to chemotherapy during adjuvant therapy were included in the platinum-sensitive cohort. Results Of 313 patients, 147 (47%) had recurrence. Median age was 64 years; 65% were stage III/IV. Median follow up was 39.3 months. Median RFS1 was 5.5 months (95% CI 0.7 -31.4). 115 patients (78%) received chemotherapy alone. Objective response was highest in the platinum-sensitive compared with the platinum-resistant cohort ((21/84; 25%) vs. (4/ 35; 11%)). In platinum-sensitive disease treated with chemotherapy, platinum-based had higher response compared to non-platinum-based regimens (18/44(41%) vs 3/41(7%) p=0.029). Response in platinum-resistant tumors to platinumbased regimens was 37%(3/8). 86% of patients with platinumresistance had progressive disease regardless of chemotherapy. 86 patients (27%) had a second recurrence, 47(55%) were platinum-sensitive and 36(77%) were treated with chemotherapy. Response to chemotherapy was 5% in those with a second recurrence. Conclusion In patients with recurrent USC deemed platinumsensitive at first recurrence, platinum-based regimens may be associated with improved response. Platinum-resistant tumors do not appear to have an optimal second-line chemotherapy regimen.
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20201114135110/https://ijgc.bmj.com/content/ijgc/30/Suppl_3/A43.2.full.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext"> <button class="ui simple right pointing dropdown compact black labeled icon button serp-button"> <i class="icon ia-icon"></i> Web Archive [PDF] <div class="menu fulltext-thumbnail"> <img src="https://blobs.fatcat.wiki/thumbnail/pdf/24/69/2469e0de061a369f0046089eebe7eb4c2b19e5ba.180px.jpg" alt="fulltext thumbnail" loading="lazy"> </div> </button> </a> <a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1136/ijgc-2020-igcs.76"> <button class="ui left aligned compact blue labeled icon button serp-button"> <i class="external alternate icon"></i> bmj.org </button> </a>